[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$flwrfAkCg6WlzLkuTjn0vQFSv5xecghQJ4xv4Yfqf94c":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":33,"phaseBuckets":44,"rows":51},"Nottingham University Hospitals NHS Trust",[4],105,false,15,3,139196,90,[13,16,19,22,24,26,28,31],{"name":14,"count":15},"Cystic Fibrosis",6,{"name":17,"count":18},"Multiple Sclerosis",5,{"name":20,"count":21},"Anesthesia",4,{"name":23,"count":21},"Covid19",{"name":25,"count":9},"Hearing Loss",{"name":27,"count":9},"Anemia",{"name":29,"count":30},"Osteoporosis",2,{"name":32,"count":30},"Mild Cognitive Impairment",[34,39],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT05123443","Longitudinal Assessment of Iron Rims in MS Lesions","2026-07-31","Blood sample provided",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06462001","BCG + MMC: Adding Mitomycin C to BCG in High-risk, Non-muscle-invasive Bladder Cancer","2026-12-01","Bacillus Calmette-Guerin Vaccine Intravesical",[45,46,47,48,49,50],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[52,78,96,118,154,181,207,233,258,276,300,328,346,364,389,407,431,455,480,507],{"intervention":43,"totalTrials":53,"cells":54},1,{"EARLY_PHASE1":55,"PHASE1":58,"PHASE2":60,"PHASE3":62,"PHASE4":74,"NA":76},{"trials":56,"activeCount":57},[],0,{"trials":59,"activeCount":57},[],{"trials":61,"activeCount":57},[],{"trials":63,"activeCount":53,"soonestReadout":42},[64],{"nctId":40,"briefTitle":41,"status":65,"phases":66,"primaryCompletion":42,"completion":42,"start":67,"enrollment":68,"conditions":69,"interventions":72},"ACTIVE_NOT_RECRUITING",[48],"2020-12-10",500,[70,71],"Transitional Cell Carcinoma","Transurethral Resection",[43,73],"Mitomycin",{"trials":75,"activeCount":57},[],{"trials":77,"activeCount":57},[],{"intervention":73,"totalTrials":53,"cells":79},{"EARLY_PHASE1":80,"PHASE1":82,"PHASE2":84,"PHASE3":86,"PHASE4":92,"NA":94},{"trials":81,"activeCount":57},[],{"trials":83,"activeCount":57},[],{"trials":85,"activeCount":57},[],{"trials":87,"activeCount":53,"soonestReadout":42},[88],{"nctId":40,"briefTitle":41,"status":65,"phases":89,"primaryCompletion":42,"completion":42,"start":67,"enrollment":68,"conditions":90,"interventions":91},[48],[70,71],[43,73],{"trials":93,"activeCount":57},[],{"trials":95,"activeCount":57},[],{"intervention":38,"totalTrials":53,"cells":97},{"EARLY_PHASE1":98,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":108},{"trials":99,"activeCount":57},[],{"trials":101,"activeCount":57},[],{"trials":103,"activeCount":57},[],{"trials":105,"activeCount":57},[],{"trials":107,"activeCount":57},[],{"trials":109,"activeCount":53,"soonestReadout":37},[110],{"nctId":35,"briefTitle":36,"status":111,"phases":112,"primaryCompletion":37,"completion":113,"start":114,"enrollment":115,"conditions":116,"interventions":117},"RECRUITING",[],"2027-07-31","2022-09-03",100,[17],[38],{"intervention":119,"totalTrials":30,"cells":120},"Forsteo",{"EARLY_PHASE1":121,"PHASE1":123,"PHASE2":136,"PHASE3":138,"PHASE4":140,"NA":152},{"trials":122,"activeCount":57},[],{"trials":124,"activeCount":57},[125],{"nctId":126,"briefTitle":127,"status":128,"phases":129,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":133,"interventions":134},"NCT01913834","Nasally and sc Administered Teriparatide in Healthy Volunteers","UNKNOWN",[46],"2014-08","2013-09",7,[29],[119,135],"CP046 PTH CriticalSorb",{"trials":137,"activeCount":57},[],{"trials":139,"activeCount":57},[],{"trials":141,"activeCount":57},[142],{"nctId":143,"briefTitle":144,"status":128,"phases":145,"primaryCompletion":146,"completion":146,"start":147,"enrollment":148,"conditions":149,"interventions":151},"NCT02955056","Ankle Fractures Treated With Teriparatide",[49],"2017-10","2016-10",10,[150],"Fracture, Ankle",[119],{"trials":153,"activeCount":57},[],{"intervention":155,"totalTrials":53,"cells":156},"Intravenous ferric carboxymaltose",{"EARLY_PHASE1":157,"PHASE1":159,"PHASE2":161,"PHASE3":163,"PHASE4":165,"NA":179},{"trials":158,"activeCount":57},[],{"trials":160,"activeCount":57},[],{"trials":162,"activeCount":57},[],{"trials":164,"activeCount":57},[],{"trials":166,"activeCount":57},[167],{"nctId":168,"briefTitle":169,"status":170,"phases":171,"primaryCompletion":172,"completion":173,"start":174,"enrollment":175,"conditions":176,"interventions":178},"NCT02057471","Intravenous Iron: Measuring Response in Anemic Surgical Patients","COMPLETED",[49],"2011-01","2012-03","2009-09",20,[177,27],"Colorectal Neoplasm",[155],{"trials":180,"activeCount":57},[],{"intervention":182,"totalTrials":53,"cells":183},"Iron isomaltoside 1000",{"EARLY_PHASE1":184,"PHASE1":186,"PHASE2":188,"PHASE3":190,"PHASE4":192,"NA":205},{"trials":185,"activeCount":57},[],{"trials":187,"activeCount":57},[],{"trials":189,"activeCount":57},[],{"trials":191,"activeCount":57},[],{"trials":193,"activeCount":57},[194],{"nctId":195,"briefTitle":196,"status":128,"phases":197,"primaryCompletion":198,"completion":198,"start":199,"enrollment":200,"conditions":201,"interventions":204},"NCT01927328","Iron Replacement in Oesophagogastric Neoplasia",[49],"2017-08","2013-08",40,[27,202,203],"Esophageal Cancer","Gastric Cancer",[182],{"trials":206,"activeCount":57},[],{"intervention":208,"totalTrials":53,"cells":209},"Metformin",{"EARLY_PHASE1":210,"PHASE1":212,"PHASE2":214,"PHASE3":216,"PHASE4":218,"NA":231},{"trials":211,"activeCount":57},[],{"trials":213,"activeCount":57},[],{"trials":215,"activeCount":57},[],{"trials":217,"activeCount":57},[],{"trials":219,"activeCount":57},[220],{"nctId":221,"briefTitle":222,"status":170,"phases":223,"primaryCompletion":224,"completion":225,"start":226,"enrollment":227,"conditions":228,"interventions":230},"NCT02972723","Metformin Therapy in HCV Infection",[49],"2011-09","2011-12","2011-03",16,[229],"Chronic Hepatitis C Infection",[208],{"trials":232,"activeCount":57},[],{"intervention":234,"totalTrials":53,"cells":235},"Ferric carboxymaltose",{"EARLY_PHASE1":236,"PHASE1":238,"PHASE2":240,"PHASE3":242,"PHASE4":244,"NA":256},{"trials":237,"activeCount":57},[],{"trials":239,"activeCount":57},[],{"trials":241,"activeCount":57},[],{"trials":243,"activeCount":57},[],{"trials":245,"activeCount":57},[246],{"nctId":247,"briefTitle":248,"status":170,"phases":249,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":253,"interventions":254},"NCT01701310","IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia",[49],"2014-12","2012-04",116,[27,177],[234,255],"Ferrous Sulphate",{"trials":257,"activeCount":57},[],{"intervention":255,"totalTrials":53,"cells":259},{"EARLY_PHASE1":260,"PHASE1":262,"PHASE2":264,"PHASE3":266,"PHASE4":268,"NA":274},{"trials":261,"activeCount":57},[],{"trials":263,"activeCount":57},[],{"trials":265,"activeCount":57},[],{"trials":267,"activeCount":57},[],{"trials":269,"activeCount":57},[270],{"nctId":247,"briefTitle":248,"status":170,"phases":271,"primaryCompletion":250,"completion":250,"start":251,"enrollment":252,"conditions":272,"interventions":273},[49],[27,177],[234,255],{"trials":275,"activeCount":57},[],{"intervention":277,"totalTrials":53,"cells":278},"Tezacaftor\u002FIvacaftor + Ivacaftor",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":294,"PHASE4":296,"NA":298},{"trials":280,"activeCount":57},[],{"trials":282,"activeCount":57},[],{"trials":284,"activeCount":57},[285],{"nctId":286,"briefTitle":287,"status":170,"phases":288,"primaryCompletion":289,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":293},"NCT04006873","Gut Imaging for Function & Transit in Cystic Fibrosis Study 2",[47],"2020-10-29","2019-09-03",12,[14],[277],{"trials":295,"activeCount":57},[],{"trials":297,"activeCount":57},[],{"trials":299,"activeCount":57},[],{"intervention":301,"totalTrials":53,"cells":302},"cotrimoxazole",{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":322,"PHASE4":324,"NA":326},{"trials":304,"activeCount":57},[],{"trials":306,"activeCount":57},[],{"trials":308,"activeCount":57},[309],{"nctId":310,"briefTitle":311,"status":312,"phases":313,"primaryCompletion":314,"completion":314,"start":315,"enrollment":148,"conditions":316,"interventions":319},"NCT01701297","VSL#3 and Spontaneous Bacterial Peritonitis","TERMINATED",[47],"2014-10","2012-02",[317,318],"Decompensated Cirrhosis","Ascites",[301,320,321],"VSL#3 active","VSL#3 placebo",{"trials":323,"activeCount":57},[],{"trials":325,"activeCount":57},[],{"trials":327,"activeCount":57},[],{"intervention":320,"totalTrials":53,"cells":329},{"EARLY_PHASE1":330,"PHASE1":332,"PHASE2":334,"PHASE3":340,"PHASE4":342,"NA":344},{"trials":331,"activeCount":57},[],{"trials":333,"activeCount":57},[],{"trials":335,"activeCount":57},[336],{"nctId":310,"briefTitle":311,"status":312,"phases":337,"primaryCompletion":314,"completion":314,"start":315,"enrollment":148,"conditions":338,"interventions":339},[47],[317,318],[301,320,321],{"trials":341,"activeCount":57},[],{"trials":343,"activeCount":57},[],{"trials":345,"activeCount":57},[],{"intervention":321,"totalTrials":53,"cells":347},{"EARLY_PHASE1":348,"PHASE1":350,"PHASE2":352,"PHASE3":358,"PHASE4":360,"NA":362},{"trials":349,"activeCount":57},[],{"trials":351,"activeCount":57},[],{"trials":353,"activeCount":57},[354],{"nctId":310,"briefTitle":311,"status":312,"phases":355,"primaryCompletion":314,"completion":314,"start":315,"enrollment":148,"conditions":356,"interventions":357},[47],[317,318],[301,320,321],{"trials":359,"activeCount":57},[],{"trials":361,"activeCount":57},[],{"trials":363,"activeCount":57},[],{"intervention":365,"totalTrials":53,"cells":366},"Sirolimus 0.5Mg Tab",{"EARLY_PHASE1":367,"PHASE1":369,"PHASE2":371,"PHASE3":383,"PHASE4":385,"NA":387},{"trials":368,"activeCount":57},[],{"trials":370,"activeCount":57},[],{"trials":372,"activeCount":57},[373],{"nctId":374,"briefTitle":375,"status":170,"phases":376,"primaryCompletion":377,"completion":377,"start":378,"enrollment":379,"conditions":380,"interventions":382},"NCT05663944","REpurposing SirolimUS in Compensated Advanced Chronic Liver Disease. the RESUS Proof of Concept Study",[47],"2024-06-25","2022-07-25",41,[381],"Advanced Chronic Liver Disease",[365],{"trials":384,"activeCount":57},[],{"trials":386,"activeCount":57},[],{"trials":388,"activeCount":57},[],{"intervention":135,"totalTrials":53,"cells":390},{"EARLY_PHASE1":391,"PHASE1":393,"PHASE2":399,"PHASE3":401,"PHASE4":403,"NA":405},{"trials":392,"activeCount":57},[],{"trials":394,"activeCount":57},[395],{"nctId":126,"briefTitle":127,"status":128,"phases":396,"primaryCompletion":130,"completion":130,"start":131,"enrollment":132,"conditions":397,"interventions":398},[46],[29],[119,135],{"trials":400,"activeCount":57},[],{"trials":402,"activeCount":57},[],{"trials":404,"activeCount":57},[],{"trials":406,"activeCount":57},[],{"intervention":408,"totalTrials":53,"cells":409},"Topical analgesia",{"EARLY_PHASE1":410,"PHASE1":412,"PHASE2":414,"PHASE3":416,"PHASE4":418,"NA":420},{"trials":411,"activeCount":57},[],{"trials":413,"activeCount":57},[],{"trials":415,"activeCount":57},[],{"trials":417,"activeCount":57},[],{"trials":419,"activeCount":57},[],{"trials":421,"activeCount":57},[422],{"nctId":423,"briefTitle":424,"status":170,"phases":425,"primaryCompletion":426,"completion":426,"start":427,"enrollment":68,"conditions":428,"interventions":430},"NCT04959409","Topical Analgesia Before Inhalational Anaesthesia",[],"2021-01-31","2020-08-01",[20,429],"Pediatric ALL",[408],{"intervention":432,"totalTrials":53,"cells":433},"Ursodeoxycholic acid",{"EARLY_PHASE1":434,"PHASE1":436,"PHASE2":438,"PHASE3":440,"PHASE4":442,"NA":444},{"trials":435,"activeCount":57},[],{"trials":437,"activeCount":57},[],{"trials":439,"activeCount":57},[],{"trials":441,"activeCount":57},[],{"trials":443,"activeCount":57},[],{"trials":445,"activeCount":57},[446],{"nctId":447,"briefTitle":448,"status":312,"phases":449,"primaryCompletion":450,"completion":450,"start":451,"enrollment":15,"conditions":452,"interventions":454},"NCT05526807","Ursodeoxycholic Acid in C. Difficile Infection",[50],"2023-12-31","2019-05-08",[453],"Clostridioides Difficile Infection",[432],{"intervention":456,"totalTrials":53,"cells":457},"Elexacaftor \u002F Ivacaftor \u002F Tezacaftor",{"EARLY_PHASE1":458,"PHASE1":460,"PHASE2":462,"PHASE3":464,"PHASE4":466,"NA":468},{"trials":459,"activeCount":57},[],{"trials":461,"activeCount":57},[],{"trials":463,"activeCount":57},[],{"trials":465,"activeCount":57},[],{"trials":467,"activeCount":57},[],{"trials":469,"activeCount":57},[470],{"nctId":471,"briefTitle":472,"status":128,"phases":473,"primaryCompletion":474,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":479},"NCT05699148","Gut Imaging for Function and Transit in Cystic Fibrosis 3 Junior",[],"2022-08-01","2023-04-01","2022-04-01",17,[14],[456],{"intervention":481,"totalTrials":53,"cells":482},"Intra-articular injection of bupivacaine in the knee joint",{"EARLY_PHASE1":483,"PHASE1":485,"PHASE2":487,"PHASE3":489,"PHASE4":491,"NA":493},{"trials":484,"activeCount":57},[],{"trials":486,"activeCount":57},[],{"trials":488,"activeCount":57},[],{"trials":490,"activeCount":57},[],{"trials":492,"activeCount":57},[],{"trials":494,"activeCount":57},[495],{"nctId":496,"briefTitle":497,"status":128,"phases":498,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":502,"interventions":505},"NCT05561010","Understanding Pain Mechanisms in Knee Osteoarthritis",[50],"2023-03","2022-10",50,[503,504],"Osteoarthritis, Knee","Chronic Pain",[481,506],"Intra-articular injection of placebo in the knee joint",{"intervention":506,"totalTrials":53,"cells":508},{"EARLY_PHASE1":509,"PHASE1":511,"PHASE2":513,"PHASE3":515,"PHASE4":517,"NA":519},{"trials":510,"activeCount":57},[],{"trials":512,"activeCount":57},[],{"trials":514,"activeCount":57},[],{"trials":516,"activeCount":57},[],{"trials":518,"activeCount":57},[],{"trials":520,"activeCount":57},[521],{"nctId":496,"briefTitle":497,"status":128,"phases":522,"primaryCompletion":499,"completion":499,"start":500,"enrollment":501,"conditions":523,"interventions":524},[50],[503,504],[481,506]]